Cipla and SBP Group sign exclusive license agreement for Rolditamig Deuderuxtecan

Used in treatment of HER2-low advanced breast cancer
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.